NCCN publishes patient education resources for gliomas

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Comprehensive Cancer Network has published the NCCN Guidelines for Patients and NCCN Quick Guide sheets for Brain Cancer – Gliomas—the first in a series of patient education resources focused on brain cancer.

Published by NCCN through support of the NCCN Foundation, and partly through funding from NCCN Foundation’s Team Pound the Pavement for Patients, these resources inform patients about their disease and the treatment options available to them.

“Access to new, easy-to-understand treatment information for patients with brain cancer empowers these patients to make informed decisions about their care. We are excited to present the new NCCN Guidelines for Patients – Gliomas and look forward to publication of the entire Brain Cancer Series,” said Marcie Reeder, executive director, NCCN Foundation.

Support from NCCN Foundation’s Team Pound the Pavement for Patients was donated in honor of Melanie Moletzsky, an employee of NCCN who was diagnosed with anaplastic astrocytoma—a type of glioma—in 2015. During her time in treatment—nearly two years—Moletzsky learned a lot about living with brain cancer and the side effects of the disease and its treatment.

She shares her insights in the new NCCN Guidelines for Patients: Brain Cancer – Gliomas. These resources are available free of charge on NCCN.org/patients, as well as on the free NCCN Patient Guides for Cancer mobile app, available for Android and iOS devices. NCCN plans to publish additional patient resources focusing on other forms of Brain Cancer in the future.

NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology, are easy-to-understand resources based on the same clinical practice guidelines used by health care professionals around the world to determine the best way to treat a patient with cancer.

NCCN currently offers NCCN Guidelines for Patients for the following:

Brain, Breast, Colon, Esophageal, Kidney, Non-Small Cell Lung, Ovarian, Pancreatic, Prostate, and Stomach Cancers; Acute Lymphoblastic Leukemia; Adolescents and Young Adults with Cancer; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Hodgkin Lymphoma; Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; Nausea and Vomiting; Non-Hodgkin’s Lymphomas; and Soft Tissue Sarcoma.

The NCCN Guidelines for Patients and NCCN Quick Guide™ sheets for Brain Cancer – Gliomas are available to download for free from NCCN.org/patients and on the NCCN Patient Guides for Cancer mobile app.

Table of Contents

YOU MAY BE INTERESTED IN

With growing evidence that molecular characterization of a tumor helps predict a patient’s prognosis and response to specific treatments, biomarker testing has been required or recommended for more than half of the 62 oncology drugs introduced over the past five years. However, health insurance policies don’t always cover tests, thus denying their clients access to precision medicine.
Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).

Login